Abstract | OBJECTIVE: METHODS: We enrolled 12 patients with FD in an open-label titration and treatment study to assess the safety of carbidopa. We then conducted a randomized, double-blind, placebo-controlled, crossover study to evaluate its antiemetic efficacy. RESULTS: Previous fundoplication surgery in each patient studied prevented vomiting, but all of the subjects experienced severe cyclical nausea and uncontrollable retching that was refractory to standard treatments. Carbidopa at an average daily dose of 480 mg (range 325-600 mg/day) was well tolerated. In the double-blind phase, patients experienced significantly less nausea and retching while on carbidopa than on placebo (p < 0.03 and p < 0.02, respectively). Twenty-four-hour urinary dopamine excretion was significantly lower while on carbidopa (147 ± 32 µg/gCr) than while on placebo (222 ± 41µg/gCr, p < 0.05). CONCLUSIONS: CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that carbidopa is effective in reducing nausea/retching/ vomiting in patients with FD.
|
Authors | Lucy Norcliffe-Kaufmann, Jose Martinez, Felicia Axelrod, Horacio Kaufmann |
Journal | Neurology
(Neurology)
Vol. 80
Issue 17
Pg. 1611-7
(Apr 23 2013)
ISSN: 1526-632X [Electronic] United States |
PMID | 23553478
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiemetics
- Dopamine Agents
- Carbidopa
|
Topics |
- Adolescent
- Adult
- Antiemetics
(therapeutic use)
- Carbidopa
(therapeutic use)
- Child
- Cross-Over Studies
- Dopamine Agents
(therapeutic use)
- Double-Blind Method
- Dysautonomia, Familial
(complications, drug therapy)
- Female
- Humans
- Male
- Nausea
(drug therapy, etiology)
- Vomiting
(drug therapy, etiology)
- Young Adult
|